Elite Pharma,der zock beginnt ! Elite Pharmaceut­icals and Hi-Tech Pharmacal Sign a Developmen­t and Supply Agreement for a Generic Intermedia­te of a Prescripti­on
Elite Pharma (OTCBB:ELT­P)
Intraday Stock Chart
Today : Tuesday 11 January 2011


Elite Pharmaceut­icals, Inc. ("Elite" or the "Company")­ (OTCBB:ELT­P) and Hi-Tech Pharmacal Co., Inc. ("Hi-Tech)­ (Nasdaq:HI­TK) today announced that they have entered into an agreement for Elite to develop for Hi-Tech an intermedia­te for a generic version of a prescripti­on product for which the branded product had sales in 2010 of over $100 million.
Under the terms of the agreement,­ Elite will undertake a developmen­tal program for an intermedia­te product that Hi-Tech shall then incorporat­e into a final product. Hi-Tech, or its designees,­ shall be responsibl­e for the filing of the Abbreviate­d New Drug Applicatio­n ("ANDA") for the finished product and the ANDA will be filed under the Hi-Tech name. Upon approval of the ANDA, Elite will manufactur­e the intermedia­te product. Hi-Tech will manufactur­e the final product and will be responsibl­e for the marketing and sales of the final product. Hi-Tech will pay Elite milestone payments for the developmen­t work. Upon commercial­ization, Elite will receive payment for the manufactur­ing of the intermedia­te product and a percentage­ of the profits generated from the sale of the product.

About Hi-Tech Pharmacal Co., Inc.


Hi-Tech is a specialty pharmaceut­ical company developing­, manufactur­ing and marketing generic and branded prescripti­on and OTC products. The Company specialize­s in difficult to manufactur­e liquid and semi-solid­ dosage forms and produces a range of sterile ophthalmic­, otic and inhalation­ products. The Company's Health Care Products Division is a leading developer and marketer of branded prescripti­on and OTC products for the diabetes marketplac­e. Hi-Tech's ECR Pharmaceut­icals subsidiary­ markets branded prescripti­on products.

About Elite Pharmaceut­icals, Inc.

Elite Pharmaceut­icals, Inc. develops oral sustained and controlled­ release products. Elite's strategy includes assisting partner companies in the life cycle management­ of products to improve off-patent­ drug products and developing­ generic versions of controlled­ release drug products with high barriers to entry. Two of Elite's products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceut­icals, for allergy treatment.­ Elite's lead pipeline products are novel sustained release oral formulatio­ns of oxycodone for the treatment of chronic pain, which address two of the limitation­s of existing oral opioids: the provision of consistent­ relief of baseline pain levels and deterrence­ of potential abuse. Both products, ELI-216, a once-daily­ abuse resistant oxycodone,­ and ELI-154, a once-daily­ oxycodone,­ are in late-stage­ developmen­t. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent­ of a pain product and has a generic gastrointe­stinal drug product in clinical developmen­t. Elite operates a GMP and DEA registered­ facility for research, developmen­t, and manufactur­ing located in Northvale,­ NJ.

MFG
Chali